Molecular-progression switching beyond ESR1
SERENA-6 showed you can act on a blood test before the scan changes. The same logic could apply to PIK3CA, AKT1, or HER2 mutations emerging on treatment.
Serial ctDNA during first-line therapy could trigger the addition of a PI3K/AKT inhibitor when PIK3CA/AKT1 mutations emerge, or T-DXd when HER2 activation appears, before radiographic progression.
Pages like this
not linked directly; found by shared links- PersonNicholas Turner
Shares Camizestrant, SERENA-6, Capivasertib, Liquid biopsy (ctDNA).
- PairingOral SERD + CDK4/6 inhibitor after ESR1 emergence
Shares Camizestrant, SERENA-6, ESR1 mutation, HR-positive / HER2-negative breast cancer.
- IdeactDNA-guided dose holidays for lung cancer targeted therapy
Shares Tumour heterogeneity and clonal evolution, Circulating tumour DNA (ctDNA), Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- Key paperGerlinger: a single biopsy misses most of the mutations in a kidney tumour
Shares A clone report from blood at every treatment cycle, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- PairingPI3K/AKT-pathway inhibitor + endocrine therapy (± CDK4/6)
Shares Inavolisib, Capivasertib, HR-positive / HER2-negative breast cancer.
- IdeaRe-test the metastasis, not the old primary, before every change of treatment
Shares Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA), HR-positive / HER2-negative breast cancer.
- IdeaLook for the resistant sub-population before the first dose
Shares Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA), HR-positive / HER2-negative breast cancer.
- IdeaTrack clones in blood with methylation patterns instead of mutations
Shares Tumour heterogeneity and clonal evolution, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).